fasting while on glp-1 Semaglutide vs. Intermittent Fasting: Which Works Best? Danger! The truth about intermittent

Efficacy of the GLP-1 receptor agonist, semaglutide, in abstinence from illicit and nonprescribed opioids in an outpatient population with treatment-refractory OUD: a randomized, double-blind, placebo-controlled clinical trial protocol

For diabetic retinopathy, the evidence was nuanced, indicating potential long-term neurovascular protection but also a risk of transient early worsening

At Coryell Health, you can sit down with someone who truly understands your history and your goals

To download the app, text* BCBSTXAPP to 33633

AnaptysBio is developing its own wholly owned PD-1 agonist candidate for rheumatoid arthritis, rosnilimab, with data expected in Q1 2025